You are here: Home » Opinion » Financial X-Ray
Business Standard

Biosimilars portfolio monetisation key for Biocon

March quarter performance weak due to delay in product approvals

Ujjval Jauhari  |  Mumbai 

Biocon’s results for the quarter ending March 2017 was muted due to longer timelines for product approvals in some emerging markets, discontinuance of some in-licenced products and impact of the fire at Syngene, its subsidiary. Research arm Syngene, which contributed about 30 per cent to overall sales, saw a 14 per cent year-on-year (y-o-y) decline in business in the March quarter as a fire in December led to a temporary disruption. The small molecules and biologics business, contributing about half to revenues, also saw flat sales. Only branded formulations saw growth of 25 ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
RECOMMENDED FOR YOU

Biosimilars portfolio monetisation key for Biocon

March quarter performance weak due to delay in product approvals

Biocon's results for the quarter ending March 2017 was muted due to longer timelines for product approvals in some emerging markets, discontinuance of some in-licensed products and impact of the fire at Syngene, its subsidiary.The research arm, Syngene, which contributed about 30 per cent to overall sales, saw a 14 per cent year-on-year decline in business in March quarter as a fire incident in December last year led to a temporary disruption. The small molecules and biologics business, contributing about half to revenues, also saw flat sales. Only branded formulations saw good growth of 25 per cent, but since it forms only 15 per cent of revenues, it was not enough to prevent overall sales from declining two per cent year-on-year to Rs 925 crore. Bloomberg consensus estimates had pegged revenues at Rs 1,061 crore.With lower sales, Ebitda at Rs 182 crore came significantly lower than estimates of Rs 253 crore. So did net profit, which at Rs 127 crore missed consensus estimates of Rs .. Biocon’s results for the quarter ending March 2017 was muted due to longer timelines for product approvals in some emerging markets, discontinuance of some in-licenced products and impact of the fire at Syngene, its subsidiary. Research arm Syngene, which contributed about 30 per cent to overall sales, saw a 14 per cent year-on-year (y-o-y) decline in business in the March quarter as a fire in December led to a temporary disruption. The small molecules and biologics business, contributing about half to revenues, also saw flat sales. Only branded formulations saw growth of 25 ... image
Business Standard
177 22

Biosimilars portfolio monetisation key for Biocon

March quarter performance weak due to delay in product approvals

Biocon’s results for the quarter ending March 2017 was muted due to longer timelines for product approvals in some emerging markets, discontinuance of some in-licenced products and impact of the fire at Syngene, its subsidiary. Research arm Syngene, which contributed about 30 per cent to overall sales, saw a 14 per cent year-on-year (y-o-y) decline in business in the March quarter as a fire in December led to a temporary disruption. The small molecules and biologics business, contributing about half to revenues, also saw flat sales. Only branded formulations saw growth of 25 ...

image
Business Standard
177 22